Ko­di­ak 're­boot­s' Eylea com­peti­tor af­ter pos­i­tive da­ta in di­a­bet­ic vi­sion loss tri­al

De­spite two failed late-stage tri­als, Pa­lo Al­to-based biotech Ko­di­ak Sci­ences said it’s go­ing to restart de­vel­op­ment of its po­ten­tial Eylea ri­val af­ter it met all its end­points in a tri­al for di­a­bet­ic retinopa­thy, which can cause blind­ness in di­a­bet­ic pa­tients.

Ko­di­ak orig­i­nal­ly paused the de­vel­op­ment pro­gram last sum­mer when it flunked two Phase III stud­ies in di­a­bet­ic mac­u­lar ede­ma when put head-to-head against Re­gen­eron’s block­buster Eylea (afliber­cept).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER